NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	62.09M 186M 54.25M 49.82M 46.46M 88.07M 5.91B 89.56M 600M 232M 2.9B 233M 228M 9.99B	P/E 2024 *	-	P/E 2025	-2.81x
Enterprise Value	60.24M 180M 52.64M 48.34M 45.08M 85.45M 5.73B 86.9M 582M 226M 2.81B 226M 221M 9.69B	EV / Sales 2024 *	-	EV / Sales 2025	-
Free-Float	35.62%	Yield 2024 *	-	Yield 2025	-

07-01	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
06-15	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
05-27	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
05-27	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
04-30	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
04-29	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
04-20	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
04-01	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
03-09	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE
01-12	Newcelx Ltd. Announces Positive Results from International Collaborative Study	CI
01-05	NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board	CI
11-17	NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory Board	CI

07-01	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes	AQ
05-27	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL
04-30	NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026	AQ
04-20	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference	GL
04-01	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADIMASTEM LTD	+1.08%	-2.83%	-	-	20.73M
LONZA GROUP AG	+0.76%	+6.25%	+2.01%	+7.29%	49.15B
REVOLUTION MEDICINES, INC.	+0.92%	+6.21%	+408.85%	+607.44%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+11.06%	+25.75%	-7.89%	34.55B
BEONE MEDICINES AG	+5.46%	+8.10%	+21.83%	+66.94%	33.09B
CELLTRION, INC.	+1.20%	+2.02%	+9.79%	+32.43%	25.19B
ASCENDIS PHARMA A/S	+2.51%	+4.94%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+7.24%	+71.03%	+132.17%	15.92B
EUROFINS SCIENTIFIC SE	+0.46%	+0.73%	+13.83%	+19.27%	13.83B
ICON PUBLIC LIMITED COMPANY	-1.14%	+7.52%	+14.75%	-30.83%	13.26B
Average	+1.26%	+6.43%	+70.98%	+103.35%	26.92B
Weighted average by Cap.	+1.34%	+6.73%	+88.46%	+131.06%

	2024	2025
Net sales	-	-
Net income	-26.55M -79.53M -23.2M -21.31M -19.87M -37.67M -2.53B -38.3M -257M -99.41M -1.24B -99.7M -97.53M -4.27B	-8.3M -24.86M -7.25M -6.66M -6.21M -11.77M -790M -11.97M -80.19M -31.08M -388M -31.16M -30.49M -1.34B
Net Debt	7.35M 22.01M 6.42M 5.9M 5.5M 10.42M 699M 10.6M 70.98M 27.51M 343M 27.59M 26.99M 1.18B	-1.85M -5.53M -1.61M -1.48M -1.38M -2.62M -176M -2.66M -17.83M -6.91M -86.2M -6.93M -6.78M -297M

Kadimastem Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

KDST

IL0011284614

Biotechnology & Medical Research

Valuation: Kadimastem Ltd

Latest news : Kadimastem Ltd

Analysts' recommendations: Kadimastem Ltd

Press Releases: Kadimastem Ltd

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile